Drug discovery, clinical, commercial.
Drug companies spend heavily and for many years to develop medicines, most of which fail, and earn it back during a limited period of patent protection. When patents expire, generic or biosimilar competitors take most of the sales, so the pipeline of new drugs is everything. Regulators decide what reaches the market; governments and insurers decide what it earns. Watch clinical trial results, approval decisions, patent expirations and drug pricing policy.
Sector journalism and trade press.
Membership bodies, advocacy, standards.
Where deals get done and announcements happen.
Sector-specialist analysts and data providers.
Agencies that govern the sector.
Bellwethers and notable executives.
Formal credentials and professional learning.